Acrux (ASX: ACR) today confirmed that Eli Lilly and Company reported global Axiron net sales of US$39.9 million in its financial results for the quarter ending 31 December 2016, up from US$39.0 Million for the previous quarter to 30 September 2016.
This is the reality of the situation (and imo, the real message of the announcement):
“Acrux (ASX: ACR) today confirmed that Eli Lilly and Company reported global Axiron net sales for the half year ended December 31, 2016 of US$78.9m, down US$4.1m or 4.94% on the previous half yearly result for 2015. It is a true like for like comparison and the fall cannot be attributed in any way to generic brands, as none have launched as yet.”
Bit of a difference, hey.
I’d be sure that when the Axiron generics are launched, we will be cannibalized big time.
ACR Price at posting:
31.5¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)